NGGT has initiated Phase I/II clinical trials in the U.S. and China to evaluate the safety and efficacy of NGGT002 for the <a ta ...

Other examples include obesity, Gaucher's disease, phenylketonuria (PKU), medium-chain acyl-CoA dehydrogenase deficiency (MCADD), maple syrup urine disease (MSUD), and hemochromatosis. These ...

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

(“Next Generation Gene Therapeutics” or “NGGT”), a clinical-stage biotechnology company pioneering the next wave of gene therapy innovation for genetic rare diseases, today announced positive new data ...

The Philippine Health Insurance Corporation (PhilHealth) endorsed five 'better benefit packages' for heart attacks, rare ...

The Philippine Health Insurance Corporation (PhilHealth) endorsed new enhanced benefit packages to the agency’s board. The ...

Group 2 encompasses diseases that need long-term or lifelong management but have relatively lower treatment costs, such as ...

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...